Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
暂无分享,去创建一个
S. Loi | W. Weichert | A. Stenzinger | C. Denkert | M. Dietel | H. Tesch | S. Loibl | M. Untch | V. Nekljudova | J. Blohmer | S. Kümmel | G. von Minckwitz | S. Darb-Esfahani | W. Schmitt | C. Jackisch | P. Sinn | C. Schem | V. Endris | T. Reimer | C. Salat | P. Klare | M. Möbs | B. Sinn
[1] D. Berry,et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Odunsi,et al. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers , 2015, OncoTarget.
[3] Carsten Denkert,et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Charles J. Vaske,et al. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53 , 2014, Molecular Cancer Research.
[5] Carsten Denkert,et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Rezai,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[7] Carlos Caldas,et al. TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance , 2014, Clinical Cancer Research.
[8] J. Valcárcel,et al. Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.
[9] Raphaël Porcher,et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. , 2013, Breast.
[10] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[11] Chao-ying Liu,et al. Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis , 2012, PloS one.
[12] Tanja Cufer,et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. , 2011, The Lancet. Oncology.
[13] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[14] M. Espié,et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. , 2010, The oncologist.
[15] A. Levine,et al. The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.
[16] Varda Rotter,et al. When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.
[17] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[18] M. Espié,et al. Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen , 2007, PLoS medicine.
[19] Charles M Perou,et al. Gene expression patterns associated with p53 status in breast cancer , 2006, BMC Cancer.
[20] M. Espié,et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy , 2002, The Lancet.
[21] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[22] W. Remmele,et al. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.
[23] S. Noguchi,et al. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer. , 2014, Cancer letters.
[24] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[25] M. Olivier,et al. Recent advances in p53 research: an interdisciplinary perspective , 2009, Cancer Gene Therapy.